Evidence map›Paper›PMID 34683956›Full record

ArticlePharmaceutics2021

Enhanced Detection of Desmoplasia by Targeted Delivery of Iron Oxide Nanoparticles to the Tumour-Specific Extracellular Matrix.

Meenu Chopra, Jiansha Wu, Yen Ling Yeow, Louise Winteringham, Tristan D Clemons, Martin Saunders, Venkata Ramana Kotamraju, Ruth Ganss, Kirk W Feindel, Juliana Hamzah

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Meenu ChopraHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Nedlands 6009, Australia.
Jiansha WuHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Nedlands 6009, Australia.ORCID 0000-0002-2341-6354
Yen Ling YeowHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Nedlands 6009, Australia.
Louise WinteringhamHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Nedlands 6009, Australia.
Tristan D ClemonsSchool of Molecular Sciences, The University of Western Australia, Crawley 6009, Australia.
Martin SaundersCentre for Microscopy, Characterisation and Analysis, The University of Western Australia, Nedlands 6009, Australia.ORCID 0000-0001-6873-7816
Venkata Ramana KotamrajuCancer Research Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Ruth GanssHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Nedlands 6009, Australia.ORCID 0000-0002-5551-045X
Kirk W FeindelCentre for Microscopy, Characterisation and Analysis, The University of Western Australia, Nedlands 6009, Australia.ORCID 0000-0002-4402-0180
Juliana HamzahHarry Perkins Institute of Medical Research, Centre for Medical Research, QEII Medical Centre, The University of Western Australia, Nedlands 6009, Australia.
The University of Western Australia · AUSanford Burnham Prebys Medical Discovery Institute · US

Funding

Cancer Council Western Australia FellowshipCancer Council Western Australia ScholarshipNational Health and Medical Research Council APP1058073National Health and Medical Research Council APP1121131National Health and Medical Research Council APP1157240
6 · The paper itself

Abstract

Diagnostic imaging of aggressive cancer with a high stroma content may benefit from the use of imaging contrast agents targeted with peptides that have high binding affinity to the extracellular matrix (ECM). In this study, we report the use of superparamagnetic iron-oxide nanoparticles (IO-NP) conjugated to a nonapeptide, CSGRRSSKC (CSG), which specifically binds to the laminin-nidogen-1 complex in tumours. We show that CSG-IO-NP accumulate in tumours, predominantly in the tumour ECM, following intravenous injection into a murine model of pancreatic neuroendocrine tumour (PNET). In contrast, a control untargeted IO-NP consistently show poor tumour uptake, and IO-NP conjugated to a pentapeptide. CREKA that bind fibrin clots in blood vessels show restricted uptake in the angiogenic vessels of the tumours. CSG-IO-NP show three-fold higher intratumoral accumulation compared to CREKA-IO-NP. Magnetic resonance imaging (MRI) T

Indexed as

CSGextracellular matrixmagnetic resonance imagingnanoparticlestumour targeting

Identifiers

PMID34683956
PMCPMC8539756
OpenAlexW3205322917

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.